Iron Infusion in Pregnancy: Crucial Facts and Potential Benefits

Iron deficiency anemia affects roughly one in five pregnant women worldwide, and intravenous iron infusions have become a key tool for treating it when oral supplements fall short. A pooled estimate across global studies puts the prevalence at about 19%, though rates vary dramatically by region and trimester.¹ The stakes are high: untreated anemia during pregnancy is linked to preterm birth, low birth weight, and long-term consequences for the child’s brain development. For many women, an iron infusion can correct the problem in a single visit when pills have failed or time is running out.

Why Iron Demands Surge During Pregnancy

Your body’s need for iron roughly doubles during pregnancy. Blood volume expands by about 50%, the placenta builds its own blood supply, and the growing fetus draws iron to lay down its own stores for the first months after birth. These competing demands mean that even women who enter pregnancy with adequate iron can become depleted by the second trimester, which is when iron deficiency anemia peaks. Global data show the burden is highest in the second trimester, at about 28%, before dropping in the third trimester as screening and treatment catch up.¹

Serum ferritin, the protein that reflects how much iron you have stored away, is the most useful blood test for catching iron deficiency before anemia develops. It is far more practical than the gold standard, which is a bone marrow biopsy, an invasive procedure no one uses for routine screening.² Ferritin can be tricky to interpret in pregnancy because it naturally dips as blood volume expands and because inflammation can push it artificially higher, but it remains the go-to test in clinical practice.

What Happens When Anemia Goes Untreated

The consequences of iron deficiency anemia during pregnancy extend to both mother and baby. In one prospective study, women with iron deficiency anemia were twice as likely to deliver preterm compared with non-anemic women (20% versus 10%), and their babies were twice as likely to have low birth weight (18% versus 9%).³ For the mother, severe anemia raises the risk of needing a blood transfusion during or after delivery and contributes to crushing fatigue that goes well beyond normal pregnancy tiredness.

The impact on the child’s developing brain is particularly concerning. Prenatal iron deficiency is associated with long-lasting changes in cognitive, social, and behavioral development, and some of these disruptions persist even after iron is eventually restored.⁴ A prospective cohort study found that children born to mothers whose ferritin was below 30 µg/L during early pregnancy scored lower on language and motor assessments at age two.⁵ Another birth cohort study linked normal maternal ferritin levels during pregnancy to better working memory and executive functioning in children at age seven.⁶ This body of evidence makes the case that treating iron deficiency early, before it deepens, is not only about the mother’s wellbeing but about giving the baby the best start neurologically.

Why Oral Iron Often Falls Short

The first-line treatment for iron deficiency in pregnancy is an oral supplement, usually a ferrous salt. In theory, this is cheap, widely available, and straightforward. In practice, oral iron has a frustrating set of limitations. The body absorbs only a small fraction of each pill, and the unabsorbed iron irritates the gut, causing nausea, constipation, cramping, and dark stools. These side effects overlap with symptoms many pregnant women already struggle with, making compliance difficult.⁷

A qualitative study of pregnant women prescribed oral iron found that gut side effects, bad memories of past tolerance issues, and simply forgetting to take pills all dragged down compliance.⁸ Even women who do manage to stick with their pills may not recover fast enough. Oral iron’s bioavailability is poor, and the rate of hemoglobin rise is gradual, often taking many weeks to make a meaningful difference. For someone diagnosed with anemia in the second or third trimester, that timeline can be uncomfortably tight before delivery.⁹

When an Iron Infusion Is Recommended

Intravenous iron is not the automatic starting point for every anemic pregnant woman. Guidelines generally point to it when one or more of the following apply: the anemia is severe, oral iron has been tried and did not work or was not tolerated, or there is a clinical need for rapid correction because delivery is approaching.¹⁰ Women with conditions that impair iron absorption through the gut, such as inflammatory bowel disease or a history of bariatric surgery, are also common candidates. In one review of post-bariatric pregnancies, over a third of women needed intravenous iron because adjusting oral doses was not enough.¹¹

Most clinicians avoid giving intravenous iron during the first trimester, largely because safety data in early pregnancy are limited and the theoretical risk-benefit balance is less clear when the pregnancy is still establishing itself. The second and third trimesters are the standard window for infusions.

How Intravenous Iron Compares to Oral

Head-to-head trials consistently show that intravenous iron raises hemoglobin faster and to a higher level than oral supplements. A randomized trial found that intravenous iron corrected iron deficiency anemia of pregnancy and restored iron stores more quickly and effectively than oral iron, with no serious adverse reactions.¹² A systematic review and meta-analysis pooling multiple trials found that hemoglobin at the time of delivery was, on average, about 0.7 g/dL higher in women treated with intravenous iron. The intravenous group also had slightly higher birth weights and, perhaps surprisingly, fewer medication reactions than the oral group.¹³ That last finding sounds counterintuitive, but oral iron’s persistent gut symptoms collectively register as reactions in trial reporting, while well-tolerated infusions often produce no symptoms at all.

A randomized trial looking at neonatal outcomes found that babies born to mothers treated with intravenous ferumoxytol had higher cord blood ferritin levels than babies of mothers who took oral iron, suggesting that the infusions helped the babies start life with better iron reserves.¹⁴ This is a potentially meaningful finding, since a newborn’s iron stores at birth supply much of what is needed during the first several months of life.

Different Intravenous Iron Formulations

Not all intravenous iron is the same product. The most commonly used formulations in obstetric care include iron sucrose, ferric carboxymaltose (FCM), ferric derisomaltose (also called iron isomaltoside), and ferumoxytol. They differ in how much iron can be delivered per session, how long the infusion takes, and their side effect profiles.

Iron sucrose has the longest track record in pregnancy and is given in smaller doses, typically requiring multiple visits. FCM allows a much larger dose in a single sitting, which is a practical advantage for a pregnant woman who may find repeated clinic visits difficult. A randomized trial comparing the two found that FCM produced a faster and higher rise in hemoglobin with fewer visits and no serious adverse events in either group.¹⁵ A meta-analysis confirmed that FCM led to higher hemoglobin and ferritin levels than iron sucrose and had a lower rate of adverse events.¹⁶

A separate systematic review that also included iron polymaltose noted that all intravenous formulations raised hemoglobin substantially, with a median increase of about 22 g/L at three to four weeks and 30 g/L by delivery. That review reported a lower rate of adverse drug reactions with iron polymaltose compared to FCM and iron sucrose, though it cautioned that none of the formulations showed clear improvements in harder clinical outcomes beyond blood counts.¹⁷ The choice of formulation often comes down to what is available at the hospital, what the local guidelines recommend, and whether a single-dose or multi-dose approach suits the patient better.

Safety and Side Effects

Modern intravenous iron formulations are considerably safer than the older high-molecular-weight iron dextran products that gave IV iron a bad reputation decades ago. Those older products carried a notable risk of serious allergic reactions, and the worst offender was removed from markets worldwide in 2009.¹⁸ Newer formulations use different carbohydrate shells to hold the iron in a stable complex, reducing the risk of free iron flooding the bloodstream. The evolution from early toxic preparations to today’s products involved developing iron cores wrapped in dextran, sucrose, or dextrin, each generation reducing the chance of anaphylaxis. The newest formulations, including FCM and ferumoxytol, no longer require a test dose and allow higher amounts of iron per infusion.¹⁹

That said, no infusion is risk-free. Common mild reactions include a metallic taste, flushing, and temporary muscle or joint aches. Serious hypersensitivity reactions are rare but can be life-threatening. Major risk factors include a previous reaction to an iron infusion, a fast infusion rate, multiple drug allergies, and severe allergic tendencies. Management requires careful monitoring during and after the infusion by trained staff.²⁰ There is at least one reported case of a fatal anaphylactic reaction to iron sucrose in a pregnant woman, a reminder that while the overall safety profile is reassuring, these infusions should always be given in a clinical setting equipped to handle emergencies.²¹

Hypophosphatemia

One side effect that has attracted growing attention is hypophosphatemia, a drop in blood phosphate levels. FCM in particular has been linked to this problem through its effect on a hormone called FGF23. In a randomized trial comparing FCM to ferumoxytol (outside pregnancy), about half of FCM-treated patients developed low phosphate levels, compared to fewer than 1% in the ferumoxytol group, and the low levels persisted for weeks in nearly a third of FCM patients.²² A postpartum study found much lower and more comparable rates of hypophosphatemia across FCM, ferric derisomaltose, and oral iron, around 2 to 3% in all groups, suggesting the magnitude of the problem may vary by setting and patient population.²³ Expert consensus now recommends monitoring phosphate levels after FCM infusions and being aware of the risk, particularly in women who may need repeated doses.²⁴

Iron Infusions After Delivery

The role of intravenous iron extends beyond pregnancy itself. Postpartum hemorrhage, which is significant blood loss around the time of delivery, can leave a new mother severely anemic at a time when she needs energy for recovery and infant care. Intravenous iron has been shown to restore hemoglobin by an average of about 2.5 g/dL within five days of infusion, with peak improvement at three to six weeks. Compared to blood transfusions, newer IV iron formulations carry a lower risk of serious adverse events and can be given as a single dose.²⁵

Fatigue is one of the most debilitating consequences of postpartum anemia, and it affects bonding, breastfeeding, and mental health. A trial of iron isomaltoside in women with severe fatigue after postpartum hemorrhage found significant reductions in physical fatigue and depression scores compared to placebo.²⁶ For women who are too anemic to wait weeks for oral iron to work, but not so severely depleted that a blood transfusion is needed, an iron infusion fills a practical gap.

Cost and Access

Intravenous iron costs more per treatment than a bottle of oral supplements. In low- and middle-income settings, where anemia rates are highest, this creates a real tension. A cost-effectiveness analysis in India found that intravenous iron sucrose cost about $87 per patient compared to $49 for oral iron, but the incremental cost per additional benefit was small relative to the country’s per capita GDP, making it a cost-effective option.²⁷ A separate Indian study confirmed that while IV iron sucrose was more expensive per patient, the cost per additional safe delivery remained well within what would be considered cost-effective in that context.²⁸

Beyond cost, practical barriers can be even harder to overcome. Research in rural India identified stock-outs of IV iron at local facilities, transport difficulties, out-of-pocket expenses, lost wages from travel, and the need for someone to accompany the patient as real-world obstacles.²⁹ In wealthier countries, access is shaped more by insurance coverage, hospital scheduling, and clinician familiarity with the infusion protocols. The bottom line for cost is that the per-treatment price is higher than pills, but the economic math tends to favor IV iron once you factor in the costs of undertreated anemia: emergency transfusions, NICU admissions for preterm or low-birth-weight infants, and longer hospital stays.

Fears, Misconceptions, and the Patient Experience

Receiving an IV iron infusion can feel intimidating, especially for women who have never had an intravenous treatment. Qualitative research in Malawi documented that many women felt anxious before their first infusion, worrying about whether their bodies would tolerate it. Some reported mild symptoms afterward, including headache, shortness of breath, or temporary vision changes, but health workers noted that only a small fraction of women experienced these effects and they resolved quickly.³⁰

More striking were the community-level misconceptions that shaped women’s willingness to accept treatment. In Malawi, myths circulated that IV iron could cause miscarriage, birth defects, or malnutrition, and some women feared that blood drawn during the procedure would be sold. These beliefs led some women to reject medical treatment in favor of traditional remedies.³¹ While these specific misconceptions may be geographically concentrated, the underlying dynamic is universal: unfamiliar medical procedures trigger anxiety, and misinformation fills the vacuum when trusted information is not available. In any setting, clear communication from the healthcare team about what to expect, how long the infusion will take, what side effects are possible, and what is being done to monitor for reactions can make a substantial difference in the experience.

What a Typical Infusion Looks Like

If you are scheduled for an iron infusion during pregnancy, the process is fairly straightforward. You will sit in a chair (or sometimes lie down) while a nurse places an IV line, usually in your arm. Depending on the formulation, the infusion itself takes anywhere from 15 minutes for FCM to a couple of hours for iron sucrose. You will be monitored during the infusion and for a short observation period afterward, typically 30 minutes, to watch for any immediate reactions.

Some women feel fine immediately and go about their day. Others feel tired or slightly off for a day or two. Mild flushing, a metallic taste in the mouth, or a headache can occur and usually resolve on their own. Your provider will likely recheck your blood counts a few weeks later to confirm that the treatment is working. In some cases, a second infusion is needed if the initial dose was not enough to fully correct the deficiency, particularly with iron sucrose, which delivers less iron per session than FCM or ferric derisomaltose.

One practical tip: eating before the infusion and staying well hydrated can reduce the chance of feeling lightheaded or nauseated. It is also worth knowing that intravenous iron can sometimes cause a brief episode of chest tightness or back pain during the infusion itself, a phenomenon that looks alarming but is usually a minor reaction to the infusion rate rather than a true allergic response. Trained infusion staff know to slow or pause the drip and reassess, and most of the time the symptoms pass quickly.

Pregnancy After Bariatric Surgery

Women who have had weight-loss surgery face an especially high risk of iron deficiency during pregnancy. Procedures like gastric bypass physically reduce the area of the small intestine where iron is absorbed, making oral supplements less effective from the start. A review of this population found that more than a third of post-bariatric pregnant women required intravenous iron because oral adjustments alone could not keep up with the demands of pregnancy.¹¹ If you have had bariatric surgery and are pregnant or planning a pregnancy, early and repeated screening of your iron status is particularly important, and the threshold for switching from oral to intravenous iron should be lower than it would be for someone with a fully intact digestive tract.